Cadomilimab Plus Oxaliplatin and Capecitabine Leads to Survi

Cadomilimab plus oxaliplatin and capecitabine leads to survival benefit in gastric/GEJ adenocarcinoma, regardless of PD-L1 expression.

Related Keywords

San Diego , California , United States , Peking , Beijing , China , Jiafu Ji , University Hospital , China National Medical Products Administration , Akeso Inc , Peking University Hospital , Enrollment Criteria , Future Directions With ,